EFFICACY AND SAFETY OF LEVOSIMENDAN IN AN ISCHEMIC CARDIOGENIC SHOCK POPULATION: A 10-YEARS SINGLE CENTRE RETROSPECTIVE STUDY
Anno:
2023
Background: Levosimendan is a Ca²⁺-sensitizer with inodilator action able to improve cardiac contractility without increse oxygen demand. In AHF setting clinical trial and registries showed an improvement in systemic haemodynamics without a decrease in in-hospital mortality. Purpose: evaluate safety and efficacy of Levosimendan in an ischemic CS population. Methods:…